MA37791A1 - Pipérazino[1,2-a]indol-1-ones et [1,4]diazépino[1,2-a]indol-1-one - Google Patents
Pipérazino[1,2-a]indol-1-ones et [1,4]diazépino[1,2-a]indol-1-oneInfo
- Publication number
- MA37791A1 MA37791A1 MA37791A MA37791A MA37791A1 MA 37791 A1 MA37791 A1 MA 37791A1 MA 37791 A MA37791 A MA 37791A MA 37791 A MA37791 A MA 37791A MA 37791 A1 MA37791 A1 MA 37791A1
- Authority
- MA
- Morocco
- Prior art keywords
- lower alkyl
- halogen
- substituted
- disorder
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
Abstract
La présente invention concerne des composés de formule générale (i), dans laquelle r1 représente hydrogène, halogène, alkyle inférieur, alcoxy inférieur, alcoxy inférieur substitué par halogène ou cyano ; r2 représente hydrogène, alkyle inférieur ou alkyle inférieur substitué par halogène ; r3 représente phényle, benzo[1,3]dioxolyle, 2,3-dihydro-benzofuran-5-yle ou un hétéroaryle à 5 et 6 chaînons, phényle et les groupes hétéroaryle à 5 et 6 chaînons pouvant être substitués par un ou plusieurs substituants choisis parmi cyano, nitro, amino et di-alkyl inférieur-amino, alkyl inférieur sulfonyle, alcoxy inférieur, alcoxy inférieur substitué par halogène, halogène, alkyle inférieur, alkyle inférieur substitué par halogène ou alkyle inférieur substitué par hydroxyle ; x représente -ch(alkyl inférieur)-, -ch2-, -ch2ch2- ou -ch(alkyl inférieur)ch2- ; r représente hydrogène ou alkyle inférieur ; n est 1 ou 2 ; ou un sel d'addition acide, pharmaceutiquement acceptable, un mélange racémique ou son énantiomère correspondant et/ou leurs isomères optiques. Les composés peuvent être utilisés pour le traitement de la schizophrénie, du trouble de la personnalité obsessionnelle-compulsive, de la dépression majeure, des troubles bipolaires, des troubles de l'anxiété, du vieillissement normal, de l'épilepsie, de la dégénescence rétinienne, du traumatisme cérébral, du traumatisme médullaire, du trouble de stress post-traumatique, du trouble panique, de la maladie de parkinson, de la démence, de la maladie d'alzheimer, du trouble cognitif léger, du dysfonctionnement cognitif induit par chimiothérapie, du syndrome de down, des troubles du spectre de l'autisme, de la perte auditive, de l'acouphène, de l'ataxie spinocérébelleuse, de la sclérose latérale amyotrophique, de la sclérose en plaques, de la maladie de huntington, de l'accident vasculaire cérébral, de la radiothérapie, du stress chronique, de l'abus de drogues neuro-actives, tels que l'alcool, les opiacés, la méthamphétamine, la phencyclidine et la cocaïne.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12179381 | 2012-08-06 | ||
| PCT/EP2013/066344 WO2014023674A1 (fr) | 2012-08-06 | 2013-08-05 | Pipérazino[1,2-a]indol-1-ones et [1,4]diazépino[1,2-a]indol-1-one |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA37791A1 true MA37791A1 (fr) | 2016-05-31 |
| MA37791B1 MA37791B1 (fr) | 2016-12-30 |
Family
ID=48918402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37791A MA37791B1 (fr) | 2012-08-06 | 2015-01-20 | Pipérazino[1,2-a]indol-1-ones et [1,4]diazépino[1,2-a]indol-1-one |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9284321B2 (fr) |
| EP (1) | EP2880036B1 (fr) |
| JP (1) | JP5974177B2 (fr) |
| KR (1) | KR101716062B1 (fr) |
| CN (1) | CN104540829B (fr) |
| AR (1) | AR092041A1 (fr) |
| AU (1) | AU2013301577B2 (fr) |
| BR (1) | BR112015000313A2 (fr) |
| CA (1) | CA2880682A1 (fr) |
| CL (1) | CL2015000143A1 (fr) |
| CO (1) | CO7141435A2 (fr) |
| CR (1) | CR20140545A (fr) |
| EA (1) | EA025884B1 (fr) |
| HK (1) | HK1206355A1 (fr) |
| IL (1) | IL236808B (fr) |
| MA (1) | MA37791B1 (fr) |
| MX (1) | MX362184B (fr) |
| MY (1) | MY185216A (fr) |
| NZ (1) | NZ703192A (fr) |
| PE (1) | PE20150341A1 (fr) |
| PH (1) | PH12015500059A1 (fr) |
| SG (1) | SG11201408529VA (fr) |
| TW (1) | TWI506027B (fr) |
| UA (1) | UA113013C2 (fr) |
| WO (1) | WO2014023674A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112924453A (zh) * | 2013-02-18 | 2021-06-08 | 赛拉诺斯知识产权有限责任公司 | 生物样品的图像分析及测量 |
| KR101767329B1 (ko) | 2013-04-02 | 2017-08-10 | 에프. 호프만-라 로슈 아게 | 피페라지노[1,2-a]인돌-1-온 및 [1,4]다이아제피노[1,2-a]인돌-1-온 |
| RU2673489C2 (ru) * | 2013-09-12 | 2018-11-27 | Ф. Хоффманн-Ля Рош Аг | Производные индолкарбоксамида |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3702321A (en) * | 1968-02-13 | 1972-11-07 | Sumitomo Chemical Co | Process for preparing benzodiazepine derivatives |
| GB0106177D0 (en) * | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
| GB0202015D0 (en) * | 2002-01-29 | 2002-03-13 | Hoffmann La Roche | Piperazine Derivatives |
| DE602006010433D1 (de) * | 2005-12-09 | 2009-12-24 | Hoffmann La Roche | Für die behandlung von obesitas geeignete tricyclische amidderivate |
| WO2008046072A2 (fr) | 2006-10-13 | 2008-04-17 | The Board Of Regents Of The University Of Texas System | Inducteurs chimiques de la neurogénèse |
| MX2009004898A (es) * | 2006-11-09 | 2009-05-19 | Hoffmann La Roche | Derivados de indol y de benzofurano-2-carboxamida. |
| DK2590647T3 (en) | 2010-07-07 | 2018-02-12 | Univ Texas | Pro-neurogenic compounds |
| KR101767329B1 (ko) * | 2013-04-02 | 2017-08-10 | 에프. 호프만-라 로슈 아게 | 피페라지노[1,2-a]인돌-1-온 및 [1,4]다이아제피노[1,2-a]인돌-1-온 |
-
2013
- 2013-08-05 BR BR112015000313A patent/BR112015000313A2/pt not_active Application Discontinuation
- 2013-08-05 TW TW102128001A patent/TWI506027B/zh not_active IP Right Cessation
- 2013-08-05 PE PE2015000024A patent/PE20150341A1/es active IP Right Grant
- 2013-08-05 UA UAA201501071A patent/UA113013C2/uk unknown
- 2013-08-05 AU AU2013301577A patent/AU2013301577B2/en not_active Ceased
- 2013-08-05 WO PCT/EP2013/066344 patent/WO2014023674A1/fr active Application Filing
- 2013-08-05 KR KR1020157003112A patent/KR101716062B1/ko active IP Right Grant
- 2013-08-05 EP EP13745648.9A patent/EP2880036B1/fr active Active
- 2013-08-05 EA EA201590125A patent/EA025884B1/ru not_active IP Right Cessation
- 2013-08-05 CA CA2880682A patent/CA2880682A1/fr not_active Abandoned
- 2013-08-05 AR ARP130102771A patent/AR092041A1/es unknown
- 2013-08-05 MX MX2015001318A patent/MX362184B/es active IP Right Grant
- 2013-08-05 MY MYPI2014003519A patent/MY185216A/en unknown
- 2013-08-05 JP JP2015525846A patent/JP5974177B2/ja active Active
- 2013-08-05 NZ NZ703192A patent/NZ703192A/en not_active IP Right Cessation
- 2013-08-05 CN CN201380041546.5A patent/CN104540829B/zh active Active
- 2013-08-05 SG SG11201408529VA patent/SG11201408529VA/en unknown
-
2014
- 2014-11-27 CR CR20140545A patent/CR20140545A/es unknown
- 2014-11-28 CO CO14262433A patent/CO7141435A2/es unknown
-
2015
- 2015-01-09 PH PH12015500059A patent/PH12015500059A1/en unknown
- 2015-01-19 IL IL236808A patent/IL236808B/en not_active IP Right Cessation
- 2015-01-20 MA MA37791A patent/MA37791B1/fr unknown
- 2015-01-21 CL CL2015000143A patent/CL2015000143A1/es unknown
- 2015-02-04 US US14/614,232 patent/US9284321B2/en active Active
- 2015-07-24 HK HK15107077.4A patent/HK1206355A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015004942A2 (pt) | benzimidazóis como agentes ativos do snc | |
| MA42442B1 (fr) | Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamate | |
| MX2016008842A (es) | Derivados de n-fenil-lactama capaces de estimular la neurogenesis y su uso en el tratamiento de trastornos neurologicos. | |
| MX2016000895A (es) | Derivados de 1,7-naftiridina. | |
| RU2014113548A (ru) | Нейроактивные стероиды, композиции и их применения | |
| AR062387A2 (es) | El uso de un compuesto derivado de imidazo[1,2-a] piridina, y un medicamento que lo contiene | |
| MA37791B1 (fr) | Pipérazino[1,2-a]indol-1-ones et [1,4]diazépino[1,2-a]indol-1-one | |
| AR093576A1 (es) | Derivados heterociclicos sustituidos | |
| MA35133B1 (fr) | Dérivés d'éthynyle comme modulateurs allostériques positifs de mglur5 | |
| JP6062078B2 (ja) | てんかん及びてんかん−関連症侯群の予防又は治療用フェニルカルバメート化合物｛ｐｈｅｎｙｌｃａｒｂａｍａｔｅｃｏｍｐｏｕｎｄｓｆｏｒｕｓｅｉｎｐｒｅｅｎｔｉｎｇｏｒｔｒｅａｔｉｎｇｐｅｄｉａｔｒｉｃｅｐｉｌｅｓｙａｎｄｅｐｉｌｅｓｙ−ｒｅｌａｔｅｄｓｙｎｄｒｏｍｅｓ｝ | |
| MX2015006364A (es) | 1,6-naftiridinas sustituidas. | |
| PH12016500605A1 (en) | Pyrido[4,3-b]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders | |
| BR112015008200A2 (pt) | derivados de imidazopiridina | |
| WO2017040879A1 (fr) | Thiazolo(3,2-a)pyrimidinone et autres composés hétérobicycliques de pyrimidinone pour utilisation à des fins thérapeutiques | |
| MX2015013915A (es) | Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona. | |
| MX2016001528A (es) | Derivados de indol-carboxamida. | |
| MX2015000629A (es) | Moduladores de benzisoxasol de neurogenesis. | |
| TH167754A (th) | ไพเพอราซิโน[1,2-a]อินดอล-1-โอนและ[1,4]ไดอะซีพิโน[1,2-a]อินดอล-1-โอน | |
| MA38457A1 (fr) | Composés à base de 1,3-oxazin-2-amine fusionnée avec du cyclopropyle perfluoré utilisables en tant qu'inhibiteurs de la bêta-sécrétase et leurs procédés d'utilisation | |
| MA34251B1 (fr) | Derives amido-tropane | |
| TH165816B (th) | ไพริโด[4,3-b]ไพราซีน-2-คาร์บอกซาไมด์ ในรูปสารก่อกำเนิดประสาทสำหรับ การรักษาความผิดปกติที่มีภาวะเสื่อมของระบบประสาท | |
| TH165816A (th) | ไพริโด[4,3-b]ไพราซีน-2-คาร์บอกซาไมด์ ในรูปสารก่อกำเนิดประสาทสำหรับ การรักษาความผิดปกติที่มีภาวะเสื่อมของระบบประสาท |